RNS News

Rep. Frank Pallone, Jr., is seeking information from six IDR entities amid concerns about No Surprises Act arbitration practices and rising healthcare costs. The post US Representative Scrutinizes Practices of IDR Entities appeared first on MedCity News.

Early intervention based on accurate diagnosis of both metabolic risk factors and acute cardiac events could help make the difference between life and death for women. The post Advancing Women’s Heart Health Through Prevention and Rapid Diagnosis appeared first on MedCity News.

GSK gained rights to a Hutchmed antibody-targeted therapy conjugate, or ATTC. This new type of targeted therapy blocks two cancer-driving proteins and will initially be developed for lung, colorectal, and pancreatic cancers. The post GSK Pays $110M for Phase 1-Ready Hutchmed Asset in a New Class of Cancer Drugs appeared first on MedCity News.

The House VA Committee voted 19-0 to subpoena Oracle Health executives Larry Ellison and Mike Sicilia after learning the VA’s EHR contract ballooned from $10 billion to $27 billion — despite Oracle’s promise to Congress that it would absorb any costs beyond the original cap. The post Oracle Health Execs Subpoenaed After VA Contract Costs Nearly Triple appeared first on MedCity News.

Ionis Pharmaceuticals’ zilganersen, brand name Zanvastro, is the first disease-modifying therapy approved for the neurological disorder Alexander disease. While Ionis has experience developing medicines for rare neuroscience indications, Zanvastro will be the first neurology product the company brings to the market without a commercialization partner. The post FDA Approves Ionis Pharma Drug, the First for Ultra-Rare Alexander Disease appeared first on MedCity News.